GlaxoSmithKline
5 Crescent Drive
Philadelphia
Pennsylvania
19112
United States
Tel: 888-825-5249
Website: http://www.gsk.com/
About GlaxoSmithKline
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2961 articles with GlaxoSmithKline
-
Malawi becomes the second country in sub-Saharan Africa to eliminate lymphatic filariasis (elephantiasis)
10/28/2020
The World Health Organization announced in this week's WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.
-
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
10/26/2020
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020 Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021 GSK to pay one-time cash payment of $60MM to AnaptysBio within 30 days GSK obtains freedom to develop and commercialize Zejula™ in combination with third party molecules $75MM in dostarlimab FDA BLA and EMA MAA regulatory filing and app
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
In the October 2 verdict, Circuit Judge Pauline Newman said that promotional materials, press releases, product catalogs, FDA labels and witness testimony did support the “induced infringement” judgement against Teva.
-
The new approval makes it the first FDA-approved therapy in over a decade to treat HES and the third indication for the therapy overall.
-
FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)
9/25/2020
GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
GSK highlights scientific advances across its growing oncology portfolio at ESMO Virtual Congress 2020
9/15/2020
Presentations across multiple tumour types, including six focused on hard-to-treat cancers in women, demonstrate progress in accelerating potentially transformational medicines
-
GlaxoSmithKline’s Trelegy Ellipta won regulatory approval for the treatment of asthma in patients aged 18 years and older.
-
FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
9/9/2020
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm
-
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
-
Biopharma Leaders Unite to Stand with Science
9/8/2020
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
-
When Moncef Slaoui was tapped to helm Operation Warp Speed, he sought confirmation that politics would not play a role in driving certain treatments through an approval process without the proper supporting scientific data to back it up.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
-
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
-
A London AI Hub, a Facility Bigger than the Louvre, Are Among the Newest Footprint Expansions in ...
9/3/2020
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence. -
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
-
Low adult immunization rates decline further due to pandemic
8/24/2020
A recent survey, conducted by The Harris Poll on behalf of GSK, finds that many adults ages 50-79 are unfamiliar with the vaccines recommended for them.